T1	Outcomes 1872 1903	vaccine-related serious adverse
T2	Outcomes 1926 1951	We recorded local adverse
T3	Outcomes 2106 2120	placebo group.
T4	Outcomes 2121 2128	Fatigue
T5	Outcomes 2421 2433	respectively
T6	Outcomes 2602 2616	placebo group.
T7	Outcomes 2617 2691	Geometric mean concentrations of IgG antibodies against Ebola glycoprotein
T8	Outcomes 2931 2966	(86路5-99路5), and 5% (0路1-24路9).
T9	Outcomes 2967 2976	Geometric
T10	Outcomes 3238 3305	participants given low-dose vaccine developed glycoprotein-specific
T11	Outcomes 3381 3390	responses
T12	Outcomes 3392 3406	INTERPRETATION
